Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACELYRIN, INC. - Common Stock
(NQ:
SLRN
)
2.270
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ACELYRIN, INC. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
October 13, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
October 12, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
October 12, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
NASDAQ:SLRN Shareholder Notice: Investigation over Possible Securities Laws Violations by Acelyrin, Inc.
↗
October 06, 2023
San Diego, CA -- (SBWIRE) -- 10/06/2023 -- An investigation was announced over potential securities laws violations by Acelyrin, Inc in connection with certain financial statements.
Via
SBWire
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
October 03, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
↗
September 30, 2023
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars.
Via
InvestorPlace
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Acelyrin Stockholders and Encourages Investors to Contact the Firm
September 28, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
↗
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Why Acelyrin Stock Plummeted 59% This Week
↗
September 15, 2023
The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate.
Via
The Motley Fool
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
September 13, 2023
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of...
Via
Benzinga
Despite Trial Setback For Acelyrin's Lead Program, Analyst Shows Optimism
↗
September 12, 2023
Acelyrin Inc (NASDAQ: SLRN) announced topline results from Part B of a Phase 2b/3 trial evaluating izokibep for moderate-to-severe Hidradenitis Suppurativa (HS).
Via
Benzinga
Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
↗
September 12, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded up 0.11% to 34,702.55 while the NASDAQ fell 0.86% to 13,797.73....
Via
Benzinga
Topics
Stocks
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
↗
September 13, 2023
Via
Benzinga
Dow Turns Higher; Oracle Shares Tumble After Q1 Results
↗
September 12, 2023
U.S. stocks traded mixed midway through trading, with the Dow Jones turning higher on Tuesday. The Dow traded up 0.22% to 34,740.15 while the NASDAQ fell 0.55% to 13,841.02. The S&P 500, also fell,...
Via
Benzinga
Topics
Stocks
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
↗
September 12, 2023
A competitor's clinical trial stumble may be benefiting MoonLake.
Via
The Motley Fool
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
↗
September 12, 2023
Benzinga
Via
Benzinga
Is American Battery Technology Company (ABML) Stock Really Up 1,300%?
↗
September 12, 2023
American Battery Technology Company (ABML) stock surprised investors Tuesday morning when it appeared to rocketing more than 1,300% higher.
Via
InvestorPlace
Dow Falls 75 Points; US Small Business Optimism Drops In August
↗
September 12, 2023
U.S. stocks traded lower this morning, with the Dow Jones falling around 75 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.22% to 34,587.58 while the NASDAQ fell 0.21%...
Via
Benzinga
Topics
Stocks
Why Is Datasea (DTSS) Stock Down 39% Today?
↗
September 12, 2023
Datasea (DTSS) stock is falling on Tuesday after the company announced a proposed public stock offering priced at 40 cents per share.
Via
InvestorPlace
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%
↗
September 12, 2023
The companies are both working on treatments for a rare skin disease.
Via
Investor's Business Daily
Why Is Acelyrin (SLRN) Stock Down 58% Today?
↗
September 12, 2023
Acelyrin (SLRN) stock is falling hard on Tuesday after the biopharma company announced lackluster clinical trial results.
Via
InvestorPlace
Why Is Skin Disorders Focused Acelyrin Stock Trading Lower Today?
↗
September 12, 2023
Acelyrin Inc (NASDAQ: SLRN) announced topline results from Part B of a Phase 2b/3 trial evaluating izokibep for moderate-to-severe
Via
Benzinga
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
↗
September 12, 2023
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
September 12, 2023
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning!
Via
InvestorPlace
Oracle, Sight Sciences And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
September 12, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
September 11, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
The Truth About IPO Investing
↗
September 02, 2023
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are...
Via
Talk Markets
Topics
Initial Public Offering
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
↗
September 05, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.